Clinical trials: in Philippines
Breast Cancer
Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
The purpose of this study is to examine the efficacy and safety as well as the characteristics of the female hormone and study medications after administration in pre-menopausal women with estrogen receptor positive advanced…
- Trial name
- NCT01073865
- Testing
- ZD9393 (Zoladex) 10.8 mg, ZD9393 (Zoladex) 3.6 mg
- Where
- 55 sites in India, Japan and 4 more
- Volunteers
- 222 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the safety profile of liraglutide under normal conditions of use.
- Trial name
- Lead-Ph (NCT01345734)
- Testing
- liraglutide
- Where
- Philippines
- Volunteers
- 1,056 people
- Sponsor
- Novo Nordisk A/S
Infections, Streptococcal
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
This study will evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™ when co-administered with DTPw-HBV/Hib and OPV or IPV vaccines, according to 2 different…
- Trial name
- NCT00344318
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Prevenar, Tritanrix-HepB
- Where
- 7 sites in Philippines, Poland
- Volunteers
- 806 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Essential Hypertension
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
- Trial name
- OSCAR (NCT00139698)
- Testing
- olmesartan alone or in combination with hydrochlorothiazide
- Where
- 32 sites in Colombia, Ecuador and 8 more
- Volunteers
- 410 people
- Sponsor
- Pfizer
Dry Eye Syndromes
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
The objectives of this study are twofold •To evaluate the safety and efficacy of 0.1% AGN-195263 administered twice daily compared to its vehicle in patients with evaporative dry eye (EDE) •To evaluate the systemic…
- Trial name
- NCT02965846
- Testing
- AGN-195263, Vehicle
- Where
- 49 sites in United States, Czechia and 10 more
- Volunteers
- 43 people
- Sponsor
- Allergan
Infections, Meningococcal
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds
The purpose of the observer-blinded study is to determine the immunogenicity and safety of one dose of GlaxoSmithKline (GSK) Biologicals' meningococcal vaccine GSK 134612 compared to one dose of Mencevax™ ACWY in healthy subjects…
- Trial name
- NCT01154088
- Testing
- Mencevax ACWY, GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]
- Where
- 3 sites in Panama, Philippines and 1 more
- Volunteers
- 1,170 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis
Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months
The trial is a phase III, non-inferiority, observer-blind, randomised, controlled, multicentre clinical trial with 2 parallel groups: IPV-Al SSI (investigational vaccine) and IPV SSI (reference vaccine)
- Trial name
- VIPV-06 (NCT03032419)
- Testing
- IPV-Al SSI, IPV SSI
- Where
- Philippines
- Volunteers
- 1,002 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Acute Heart Failure
Global Non-interventional Heart Failure Disease Registry
The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide.
- Trial name
- REPORT-HF (NCT02595814)
- Where
- 346 sites in United States, Algeria and 42 more
- Volunteers
- 18,805 people
- Sponsor
- Novartis Pharmaceuticals
Partial Epilepsy in Children and Adolescents
Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
The purpose of this study is to examine the efficacy and safety of Eslicarbazepine acetate (BIA 2-093) when given with other anti-epileptic drugs to treat children with partial seizures whose condition has not been controlled by…
- Trial name
- NCT00988156
- Testing
- Eslicarbazepine acetate (BIA 2-093), Eslicarbazepine acetate
- Where
- 91 sites in Austria, Bosnia and Herzegovina and 19 more
- Volunteers
- 304 people
- Sponsor
- Bial - Portela C S.A.
Arthritis, Rheumatoid
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis
The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis.
- Trial name
- NCT00413699
- Testing
- CP-690,550
- Where
- 469 sites in United States, Argentina and 41 more
- Volunteers
- 4,488 people
- Sponsor
- Pfizer
Heart Failure, Influenza
Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)
A multi-centre, randomized, placebo controlled, trial. Participants at high-risk for vascular events from the network of INTER- CHF will be randomized to inactivated influenza vaccine or placebo and followed prospectively over…
- Trial name
- RCT-IVVE (NCT02762851)
- Testing
- Sterile saline, inactivated trivalent influenza vaccine
- Where
- 13 sites in Cameroon, China and 11 more
- Volunteers
- 5,000 people
- Sponsor
- McMaster University
Heart Failure
Influenza Vaccine To Prevent Adverse Vascular Events:Pilot
A multi-centre, randomized, placebo controlled, trial. Participants at high-risk for vascular events from the network of INTER- CHF will be randomized to inactivated influenza vaccine or placebo and followed prospectively over…
- Trial name
- IVVE:Pilot (NCT01945268)
- Testing
- inactivated trivalent influenza vaccine, Sterile saline
- Where
- 3 sites in Mozambique, Philippines and 1 more
- Volunteers
- 107 people
- Sponsor
- McMaster University
Pulmonary Disease, Chronic Obstructive
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with…
- Trial name
- NCT02164513
- Testing
- fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
- Where
- 998 sites in United States, Argentina and 35 more
- Volunteers
- 10,355 people
- Sponsor
- GlaxoSmithKline
Influenza
An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of GSK Biologicals' influenza candidate vaccine GSK2321138A when compared to non-influenza vaccine comparators in children 6 to 35 months of age.
- Trial name
- NCT01439360
- Testing
- Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A, Havrix Junior, Prevenar 13
- Where
- 103 sites in Bangladesh, Belgium and 11 more
- Volunteers
- 12,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Meningococcal
Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults
The purpose of this study is to demonstrate, in 18-55 year old adults, the consistency of different manufactured lots of meningococcal vaccine GSK134612, the non-inferiority of GSK134612 compared to licensed meningococcal vaccine…
- Trial name
- NCT00453986
- Testing
- Meningococcal vaccine GSK134612, Mencevax™ACWY, Fluarix™
- Where
- 4 sites in Lebanon, Philippines
- Volunteers
- 1,352 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.
- Trial name
- NCT01626456
- Testing
- ALKS 9072, Low, ALKS 9072, High
- Where
- 82 sites in United States, Bulgaria and 6 more
- Volunteers
- 478 people
- Sponsor
- Alkermes, Inc.
Influenza
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
This study is designed to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational vaccine GSK2321138A in children aged 3 to 17 years, and to describe safety and immunogenicity of the GSK…
- Trial name
- NCT01196988
- Testing
- Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
- Where
- 59 sites in United States, Czechia and 3 more
- Volunteers
- 3,027 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mucopolysaccharidosis II
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
AGT-182 is a fusion protein containing idursulfase that is intended to deliver the enzyme peripherally and to the brain, when administered intravenously.
- Trial name
- NCT02262338
- Testing
- AGT-182
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- ArmaGen, Inc
Cancer
Breast Cancer With Over-expression of erbB2-BRAINSTORM
This retrospective cohort study aims to improve our understanding of the current paradigm for treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region.
- Trial name
- NCT01064349
- Testing
- Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer
- Where
- 10 sites in Philippines, Singapore and 1 more
- Volunteers
- 144 people
- Sponsor
- GlaxoSmithKline
Non Small Cell Lung Cancer (NSCLC)
Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment
The purpose of this study is to provide gefitinib treatment to patients who, on completion or closure of other gefitinib clinical studies, were either receiving placebo treatment, or are continuing on the same dose and regimen of…
- Trial name
- NCT00683306
- Testing
- ZD1839 (Iressa)
- Where
- 65 sites in Argentina, Australia and 17 more
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.